Scientific and technological prospection of potential immunotherapies including anti-cancer vaccines with a focus on osteosarcoma




Immunotherapy; Osteosarcoma; Anticancer vaccines.


Osteosarcoma (OS) is a malignant bone tumor whose treatment is performed through surgical removal associated with combined chemotherapy, which include the use of medications. In order to verify the importance of immunotherapy in a scientific way, researches were carried out in order to confirm the relevance that the study presents as a technological innovation. For this, the PubMed and Science Direct article libraries were accessed to carry out a scientific prospection, a quantity of 278 and 40 with the associations of the descriptors "Bone Neoplasms AND cancer vaccines" and "Osteosarcoma AND cancer vaccines" were obtained, respectively. Regarding technological prospecting, the same descriptors were used and searches were performed in Google Patents, selecting the WO and BR offices when necessary, using the descriptors "bone neoplasms", "osteosarcoma" and "cancer vaccines", presenting a a total of 62,610, 20410 and 34337 patents, respectively for the WO office. In the BR office, 687, 613 and 585 respectively were found. Among these findings, it was possible to notice that the search for immunotherapies for OS is growing, however, the use of vaccines for OS were more present in scientific than in technological prospecting, this can be attributed to the technology of therapeutic vaccines being recent. From these results, it can be concluded that the study provided data from scientific-technological prospection, which can help direct research, highlighting the relevance of prospective technological analysis as an opportunity to invest in intellectual property as a solution to social and economic needs.


Argenziano, M., Tortora, C., Pota, E., Paola, A. di, Martino, M. di, Leva, C. di, Pinto, D. di, & Rossi, F. (2021). Osteosarcoma in Children: Not Only Chemotherapy. Pharmaceuticals 2021, Vol. 14, Page 923, 14(9), 923.

Cabrera-Andrade, A., López-Cortés, A., Jaramillo-Koupermann, G., González-Díaz, H., Pazos, A., Munteanu, C. R., Pérez-Castillo, Y., & Tejera, E. (2020). A Multi-Objective Approach for Anti-Osteosarcoma Cancer Agents Discovery through Drug Repurposing. Pharmaceuticals, 13(11), 1–16.

Chevallier, P., Saiagh, S., Dehame, V., Guillaume, T., Peterlin, P., Bercegeay, S., le Bris, Y., Bossard, C., Gauvrit, I., Dreno, B., Juge-Morineau, N., Béné, M. C., & Gregoire, M. (2021). A phase I/II feasibility vaccine study by autologous leukemic apoptotic corpse-pulsed dendritic cells for elderly AML patients. Human Vaccines & Immunotherapeutics, 17(10), 3511–3514.

Corre, I., Verrecchia, F., Crenn, V., Redini, F., & Trichet, V. (2020). The Osteosarcoma Microenvironment: A Complex but Targetable Ecosystem. Cells, 9(4).

Cortini, M., Avnet, S., & Baldini, N. (2017). Mesenchymal stroma: Role in osteosarcoma progression. Cancer Letters, 405, 90–99.

Chueke, G. V., & Amatucci, M. (2015). O que é bibliometria? Uma introdução ao Fórum. Internext, 10(2), 1–5.

del Giudice, F., Busetto, G. M., Gross, M. S., Maggi, M., Sciarra, A., Salciccia, S., Ferro, M., Sperduti, I., Flammia, S., Canale, V., Chung, B. I., Conti, S. L., Eisenberg, M. L., Skinner, E. C., & de Berardinis, E. (2021). Efficacy of three BCG strains (Connaught, TICE and RIVM) with or without secondary resection (re-TUR) for intermediate/high-risk non-muscle-invasive bladder cancers: results from a retrospective single-institution cohort analysis. Journal of Cancer Research and Clinical Oncology, 147(10), 3073–3080.

Erp, A. E. M. van, Versleijen-Jonkers, Y. M. H., Hillebrandt-Roeffen, M. H. S., Houdt, L. van, Gorris, M. A. J., Dam, L. S. van, Mentzel, T., Weidema, M. E., Savci-Heijink, C. D., Desar, I. M. E., Merks, H. H. M., Noesel, M. M. van, Shipley, J., Graaf, W. T. A. van der, Flucke, U. E., Meyer-Wentrup, F. A. G., van Erp, A. E. M., Versleijen-Jonkers, Y. M. H., Hillebrandt-Roeffen, M. H. S., & Meyer-Wentrup, F. A. G. (2017). Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8 + lymphocytes in primary sarcomas is subtype dependent. Oncotarget, 8(41), 71371–71384.

F, J., S, J., S, S., A, N., A, S., D, R., & S, D. (2020). Osteosarcoma: A comprehensive review of management and treatment strategies. Annals of Diagnostic Pathology, 49.

Firnhaber, C., Swarts, A., Jezile, V., Mulongo, M., Goeieman, B., Williams, S., Faesen, M., Michelow, P., & Wilkin, T. (2021). Human Papillomavirus Vaccination Prior to Loop Electroexcision Procedure Does Not Prevent Recurrent Cervical High-grade Squamous Intraepithelial Lesions in Women Living With Human Immunodeficiency Virus: A Randomized, Double-blind, Placebo-controlled Trial. Clinical Infectious Diseases, 73(7), e2211–e2216.

Guerra, M. R., Bustamante-Teixeira, M. T., Corrêa, C. S. L., de Abreu, D. M. X., Curado, M. P., Mooney, M., Naghavi, M., Teixeira, R., França, E. B., & Malta, D. C. (2017). Magnitude e variação da carga da mortalidade por câncer no Brasil e Unidades da Federação, 1990 e 2015. Revista Brasileira de Epidemiologia, 20, 102–115.

Hu, G., Cheng, Z., Wu, Z., & Wang, H. (2019). Identification of potential key genes associated with osteosarcoma based on integrated bioinformatics analyses. Journal of Cellular Biochemistry, 120(8), 13554–13561.

IC, O., R, B., O, A., II, O., & G, A. (2021). Evaluation of possible effects of Persea americana seeds on female reproductive hormonal and toxicity profile. Journal of Ethnopharmacology, 273.

Ishikawa, T., Kageyama, S., Miyahara, Y., Okayama, T., Kokura, S., Wang, L., Sato, E., Yagita, H., Itoh, Y., & Shiku, H. (2021). Safety and antibody immune response of CHP-NY-ESO-1 vaccine combined with poly-ICLC in advanced or recurrent esophageal cancer patients. Cancer Immunology, Immunotherapy 2021 70:11, 70(11), 3081–3091.

John D; WICK, M. R. (2018). The American Cancer Society’s Principles of Oncology. The American Cancer Society’s Principles of Oncology.

Kaur Sarhadi, V., Daddali, R., Seppänen-Kaijansinkko, R., Pathogenesis, O., Klimczak, A., Kaltschmidt, C., & Mertzlufft, F. (2021). Mesenchymal Stem Cells and Extracellular Vesicles in Osteosarcoma Pathogenesis and Therapy. International Journal of Molecular Sciences 2021, Vol. 22, Page 11035, 22(20), 11035.

Lugowska, I., Teterycz, P., & Rutkowski, P. (2018). Immunotherapy of melanoma. Contemporary Oncology (Poznan, Poland), 22(1A), 61–67.

M, P., Y, L., W, G., Z, S., Z, W., & L, L. (2021). Recent Advances in Epigenetics of Macrovascular Complications in Diabetes Mellitus. Heart, Lung & Circulation, 30(2), 186–196.

MA, A., C, E.-B., MH, E., YO, E., M, M., D, J., TS, A. S., F, K., C, M., E, M., I, O., N, D., & AH, E. (2020). Novel therapeutic strategies for spinal osteosarcomas. Seminars in Cancer Biology, 64, 83–92.

Marcião, L. G. de A., Sousa, V. N. F. de, Lima, P. E., Lima, L. H. C., Marcião, E. F., Alves, E. L. C., Lira, J. V. M., Moura, L. F. de, Olivetto, M. M. S., Silva, G. da, Ferreira, O. P. C., Rodrigues, A. G., Alves, C. P., Viana, J. B., & Alencar, I. de. (2021). A importância da atenção Fisioterapêutica nos cuidados paliativos em pacientes com câncer. Research, Society and Development, 10(6), e46310616042.

Martin, N. T., & Bell, J. C. (2018). Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones. Molecular Therapy, 26(6), 1414–1422.

MF, W., LM, W., & TP, C. (2018). Immunotherapy for osteosarcoma: Where do we go from here? Pediatric Blood & Cancer, 65(9).

Misaghi, A., Goldin, A., Awad, M., & Kulidjian, A. A. (2018). Osteosarcoma: a comprehensive review. SICOT-J, 4.

Miwa, S., Shirai, T., Yamamoto, N., Hayashi, K., Takeuchi, A., Igarashi, K., & Tsuchiya, H. (2019). Current and Emerging Targets in Immunotherapy for Osteosarcoma. Journal of Oncology, 2019.

Mutsaers, A. J., & Walkley, C. R. (2014). Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone, 62, 56–63.

Saba, K. H., Cornmark, L., Rissler, M., Fioretos, T., Åström, K., Haglund, F., Rosenberg, A. E., Brosjö, O., & Nord, K. H. (2019). Genetic profiling of a chondroblastoma-like osteosarcoma/malignant phosphaturic mesenchymal tumor of bone reveals a homozygous deletion of CDKN2A, intragenic deletion of DMD, and a targetable FN1-FGFR1 gene fusion. Genes, Chromosomes & Cancer, 58(10), 731–736.

Sadykova, L. R., Ntekim, A. I., Muyangwa-Semenova, M., Rutland, C. S., Jeyapalan, J. N., Blatt, N., & Rizvanov, A. A. (2020). Epidemiology and Risk Factors of Osteosarcoma. Cancer Investigation, 38(5), 259–269.

Tadano, H., Tsukahara, T., Mizushima, E., Akamatsu, A., Watanabe, K., Nojima, I., Kubo, T., Kanaseki, T., Hirohashi, Y., Sato, N., & Torigoe, T. (2020). Development of an artificial antibody specific for HLA/peptide complex derived from cancer stem-like cell/cancer-initiating cell antigen DNAJB8. British Journal of Cancer 2020 123:9, 123(9), 1387–1394.

Verheust, C., Goossens, M., Pauwels, K., & Breyer, D. (2012). Biosafety aspects of modified vaccinia virus Ankara (MVA)-based vectors used for gene therapy or vaccination. Vaccine, 30(16), 2623–2632.

Vreeland, T. J., Clifton, G. T., Hale, D. F., Chick, R. C., Hickerson, A. T., Cindass, J. L., Adams, A. M., Bohan, P. M. K., Andtbacka, R. H. I., Berger, A. C., Jakub, J. W., Sussman, J. J., Terando, A. M., Wagner, T., Peoples, G. E., & Faries, M. B. (2021). A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis. Annals of Surgical Oncology, 28(11), 6126–6137.

Wang, S. D., Li, H. Y., Li, B. H., Xie, T., Zhu, T., Sun, L. L., Ren, H. Y., & Ye, Z. M. (2016). The role of CTLA-4 and PD-1 in anti-tumor immune response and their potential efficacy against osteosarcoma. International Immunopharmacology, 38, 81–89.

Watanabe, N., McKenna, M. K., Rosewell Shaw, A., & Suzuki, M. (2021). Clinical CAR-T Cell and Oncolytic Virotherapy for Cancer Treatment. Molecular Therapy, 29(2), 505–520.

Y, Z., N, S., TT, C., O, K., RL, B., YB, M., HS, L., ES, K., & SS, W. (2020). Vaccine efficacy against primary and metastatic cancer with in vitro-generated CD103 + conventional dendritic cells. Journal for Immunotherapy of Cancer, 8(1).

Yalçın, S., Yalçınkaya, S., & Ercan, F. (2021). In silico detection of inhibitor potential of Passiflora compounds against SARS-Cov-2(Covid-19) main protease by using molecular docking and dynamic analyses. Journal of Molecular Structure, 1240.

Younis, J., al Antably, I., Zamzam, M., Salem, H., Zaki, E., & Hassanian, O. (2019). Role of 18 F-fluorodeoxyglucose positron emission tomography/computed tomography and magnetic resonance imaging in prediction of response to neoadjuvant chemotherapy in pediatric osteosarcoma. World Journal of Nuclear Medicine, 18(4), 378.

Zhang, Y., Yang, J., Zhao, N., Wang, C., Kamar, S., Zhou, Y., He, Z., Yang, J., Sun, B., Shi, X., Han, L., & Yang, Z. (2018). Progress in the chemotherapeutic treatment of osteosarcoma. Oncology Letters, 16(5), 6228.



How to Cite

SANTOS, T. B. dos .; GOMES, D. dos S. .; SOUSA , A. B. F. de .; RODRIGUES, Ítalo S. G. .; PADILHA, F. F.; DROPPA-ALMEIDA, D. Scientific and technological prospection of potential immunotherapies including anti-cancer vaccines with a focus on osteosarcoma. Research, Society and Development, [S. l.], v. 10, n. 17, p. e132101723015, 2021. DOI: 10.33448/rsd-v10i17.23015. Disponível em: Acesso em: 17 jan. 2022.



Health Sciences